Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 394

The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.

Recurrence patterns across medulloblastoma subgroups: an integrated clinical and molecular analysis

Open access
Ramaswamy, Vijay, Remke, Marc, Bouffet, Eric, Faria, Claudia C, Perreault, Sebastien, Cho, Yoon-Jae, Shih, David J, Luu, Betty, Dubuc, Adrian M, Northcott, Paul A, Schüller, Ulrich, Gururangan, Sridharan, McLendon, Roger, Bigner, Darell, Fouladi, Maryam, Ligon, Keith L, Pomeroy, Scott L, Dunn, Sandra, Triscott, Joanna, Jabado, Nada, Fontebasso, Adam, Jones, David T W, Kool, Marcel, Karajannis, Matthias A, Gardner, Sharon L, Zagzag, David, Nunes, Sofia, Pimentel, José, Mora, Jaume, Lipp, Eric, Walter, Andrew W, Ryzhova, Marina, Zheludkova, Olga, Kumirova, Ella, Alshami, Jad, Croul, Sidney E, Rutka, James T, Hawkins, Cynthia, Tabori, Uri, Codispoti, Kari-Elise T, Packer, Roger J, Pfister, Stefan M, Korshunov, Andrey, Taylor, Michael D·2013·The Lancet Oncology

Abstract

Background Recurrent medulloblastoma is a daunting therapeutic challenge as it is almost universally fatal. Recent studies confirmed that medulloblastoma comprises four distinct subgroups. We sought to delineate subgroup specific differences in medulloblastoma recurrence patterns. Methods We retrospectively identified a discovery cohort of all recurrent medulloblastomas at the Hospital for Sick Children between 1994-2012, and performed molecular subgrouping on FFPE tissues using a nanoString-based assay. The anatomical site of recurrence (local tumour bed or leptomeningeal metastasis), time to recurrence and survival post-recurrence were determined in a subgroup specific fashion. Subgroup specific recurrence patterns were confirmed in two independent, non-overlapping FFPE validation cohorts. Where possible molecular subgrouping was performed on tissue obtained from both the initial surgery and at recurrence. Results A screening cohort of 30 recurrent medulloblastomas was assembled; nine with local recurrences, and 21 metastatic. When re-analysed in a subgroup specific manner, local recurrences were more frequent in SHH tumours (8/9, 88%) and metastatic recurrences were more common in Group 3 and 4 (17/20 [85%] with one WNT, p=0.0014, local vs metastatic recurrence, SHH vs Group 3 vs Group 4). The subgroup specific location of recurrence was confirmed in a multicenter validation cohort (p=0·0013 for local vs metastatic recurrence SHH vs Group 3 vs Group 4, n=77), and a second independent validation cohort comprising 96 recurrences (p<0·0001 for local vs metastatic recurrence SHH vs Group 3 vs Group 4, n=96). Treatment with craniospinal irradiation at diagnosis was not significantly associated with the anatomical pattern of recurrence. Survival post recurrence was significantly longer in Group 4 patients (p=0·013) as confirmed in a multicenter validation cohort (p=0·0075). Strikingly, subgroup affiliation remained stable at recurrence in all 34 cases with available matched primary and recurrent pairs. Conclusions Medulloblastoma does not switch subgroup at the time of recurrence further highlighting the stability of the four principle medulloblastoma subgroups. Significant differences in the location and timing of recurrence across medulloblastoma subgroups were observed which have potential treatment ramifications. Specifically, intensified local (posterior fossa) therapy should be tested in the initial treatment of SHH patients. Refinement of therapy for Groups 3 and 4 should focus on the metastatic compartment, as it is the near universal cause of patient deaths.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/s1470-2045(13)70449-2

Cites

30 of 30 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 30 references

Cited by

See all 394

Metadata

Authors
Ramaswamy, V., Remke, M., Bouffet, E., Faria, C. C., Perreault, S., Cho, Y.-J., Shih, D. J., Luu, B., Dubuc, A. M., Northcott, P. A., Schüller, U., Gururangan, S., McLendon, R., Bigner, D., Fouladi, M., Ligon, K. L., Pomeroy, S. L., Dunn, S., Triscott, J., Jabado, N., Fontebasso, A., Jones, D. T. W., Kool, M., Karajannis, M. A., Gardner, S. L., Zagzag, D., Nunes, S., Pimentel, J., Mora, J., Lipp, E., Walter, A. W., Ryzhova, M., Zheludkova, O., Kumirova, E., Alshami, J., Croul, S. E., Rutka, J. T., Hawkins, C., Tabori, U., Codispoti, K.-E. T., Packer, R. J., Pfister, S. M., Korshunov, A., & Taylor, M. D.
Venue
The Lancet Oncology
Publisher
Elsevier BV
Published
2013-11
Volume
14
Issue
12
Pages
1200-1207
ISSN
1470-2045 (ISSN-L)
OpenAlex
W2138746991
Cited by
394
References
30
FWCI
10.95
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Recurrence patterns across medulloblastoma subgroups: an integrated clinical and molecular analysis. https://app.cochat.ai/papers/10.1016/s1470-2045(13)70449-2
The paper
Ramaswamy, V., Remke, M., Bouffet, E., Faria, C. C., Perreault, S., Cho, Y.-J., Shih, D. J., Luu, B., Dubuc, A. M., Northcott, P. A., Schüller, U., Gururangan, S., McLendon, R., Bigner, D., Fouladi, M., Ligon, K. L., Pomeroy, S. L., Dunn, S., Triscott, J., . . . Taylor, M. D. (2013). Recurrence patterns across medulloblastoma subgroups: an integrated clinical and molecular analysis. The Lancet Oncology. https://doi.org/10.1016/s1470-2045(13)70449-2

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.